Artera Achieves Nationwide Access for its ArteraAI Prostate Test with New York State License

Clinicians and patients throughout New York State can now access personalized, actionable insights to inform prostate cancer treatment decisions

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today it has received its New York laboratory permit from its Department of Health. This licensure allows Artera to offer the award-winning ArteraAI Prostate Test to one of the largest healthcare markets and makes the test available to all patients across the United States.

This milestone comes on the heels of Artera’s recent announcement that its test is now updated with new insights to help higher-risk patients optimize treatment decisions. This advancement was supported by newly presented validation data, which was selected for Best of ASCO 2025.

The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. Starting on June 4th, clinicians and patients in New York can access data-backed insights to personalize cancer treatment decisions.

“Receiving the New York lab license is a significant milestone for Artera,” said Andre Esteva, CEO and co-founder of Artera. “Prostate cancer is one of the most common cancers, with the NY State Department of Health estimating that more than 15,000 men are diagnosed each year in New York alone. One of my founding goals was to increase access to AI-enabled precision medicine tools, and I’m proud our team has accomplished this in record time.”

New York State inspectors examined laboratory staff qualifications, equipment, facilities, safety program, record, and overall management to ensure the highest standard of care for all laboratory patients. This license follows the College of American Pathologists (CAP) accreditation Artera received in August and the State of California license in October of last year. Together, these certifications underscore Artera’s commitment to quality and patient safety.

“We are thrilled that the ArteraAI Prostate Test is now available in New York,” said Himanshu Nagar, MD, Director of Genitourinary Cancer, Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. “This test complements existing biomarkers by integrating multimodal AI analysis of both digital pathology and clinical data, providing an additional layer of precision in risk stratification. By leveraging AI-driven insights, it enhances our ability to personalize treatment decisions, ensuring that patients receive the most appropriate therapy while minimizing unnecessary interventions.”

About Artera

Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test.

Artera’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials.

Artera’s laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera’s laboratory in Jacksonville, Florida, and can be ordered online at Artera.ai.